VKTX - バイキング・セラピュ―ティクス (Viking Therapeutics Inc.) バイキング・セラピュ―ティクス

 VKTXのチャート


 VKTXの企業情報

symbol VKTx
会社名 Viking Therapeutics Inc (バイキング・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 バイキング・セラピューティクス(Viking Therapeutics Inc.)は臨床段階バイオ医薬品会社である。同社は代謝及び内分泌障害治療法の開発に焦点を当てる。そのリード臨床プログラムVK5211は、第II相臨床試験下での経口投与可能な薬剤候補である。第二の臨床プログラムは、高コレステロール血症及び非アルコール性脂肪性肝炎(NASH)等副腎白質ジストロフィー(ALD)及び脂質障害のための甲状腺受容体ベータ(TRB)の分子アゴニストの開発に焦点を当てる。同社はまた、ALDの治療・潜在性予防のためのVK2809及びVK0214の開発に従事する。VK0612は、2型糖尿病ための経口投与可能な第IIb相対応薬剤候補である。同社の前臨床プログラムは、貧血治療用エリスロポエチン受容体(EPOR)アゴニストの同定、及び肥満症及び脂質異常症治療用ジアシルグリセロールアシルトランスフェラーゼ-1(DGAT-1)の組織・選択的阻害剤の開発に焦点を当てる。   バイキング・セラピュ―ティクスは米国のバイオ医薬品メ―カ―。代謝及び内分泌疾患のための新規治療法の開発に焦点を当てる。主な臨床プログラムには、股関節骨折手術後のための非ステロイド系アンドロゲン受容体モジュレ―タ―の経口薬「VK5211」がある。また、副腎白質ジストロフィ―のための、小分子で経口投与可能な甲状腺受容体ベ―タを開発中。   Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The company's clinical program VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.
本社所在地 12340 El Camino Real Suite 250 San Diego CA 92130 USA
代表者氏名 Lawson Macartney ローソン・マッカートニー
代表者役職名 independent Chairman of the Board
電話番号 +1 858-704-4660
設立年月日 41153
市場名 NASDAQ Small Cap
ipoyear 2015年
従業員数
url www.vikingtherapeutics.com
nasdaq_url https://www.nasdaq.com/symbol/vktx
adr_tso
EBITDA EBITDA(百万ドル) -20.84878
終値(lastsale) 14.74
時価総額(marketcap) 894095883.56
時価総額 時価総額(百万ドル) 973.01920
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 830.85320
当期純利益 当期純利益(百万ドル) -20.40713
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Viking Therapeutics Inc revenues was not reported. Net loss decreased 2% to $10.2M. Lower net loss reflects Interest Expense/Income - Net increase from $3K (expense) to $573K (income) Change in fair value of debt conversion increase of 65% to $1.4M (income) Amortization of financing costs decrease of 88% to $60K (expense).

 VKTXのテクニカル分析


 VKTXのニュース

   The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More  2020/03/03 12:51:51 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 2) Forty Seven Inc (NASDAQ: FTSV )( announced a deal to be bought by Gilead Sciences, Inc. (NASDAQ: GILD )) IGM Biosciences Inc (NASDAQ: IGMS ) Iovance Biotherapeutics Inc (NASDAQ: IOVA ) Karyopharm Therapeutics Inc (NASDAQ: KPTI )(announced positive late-stage results for selinexor) Passage Bio Inc (NASDAQ: PASG )(IPOed Friday) Syneos Health Inc (NASDAQ: SYNH ) Trillium Therapeutics Inc (NASDAQ: TRIL )(moved in sympathy with Forty Seven, as it has a similar drug in the pipeline for solid tumor) Zynex Inc. (NASDAQ: ZYXI ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 2) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Akorn, Inc. (NASDAQ: AKRX ) ANI Pharmaceuticals Inc (NASDAQ: ANIP )(moved lower despite FDA nod for a generic version of Teva Pharmaceutical Industries Ltd's (NYSE: TEVA ) Alzheimer's related dementia drug) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Eagle Pharmaceuticals Inc (NASDAQ: EGRX ) (reacted to its fourth-quarter results) Evolus Inc (NASDAQ: EOLS ) EXACT Sciences Corporation (NASDAQ: EXAS ) GenMark Diagnostics, Inc (NASDAQ: GNMK ) Imv Inc (NASDAQ: IMV ) Neurometrix Inc (NASDAQ: NURO ) Portola Pharmaceuticals Inc (NASDAQ: PTLA ) Precigen Inc (NASDAQ: PGEN ) Taro Pharmaceutical Industries Ltd. (NYSE: TARO ) Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) TherapeuticsMD Inc (NASDAQ: TXMD ) Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) Viking Therapeutics Inc (NASDAQ: VKTX ) Related Link: How The COVID-19 Outbreak Is Benefiting Biotech Investors Stocks In Focus GenMark Starts Shipping COVID-19 Test Kits GenMark said it has begun shipping ePlex Research Use Only, or RUO, test kits to detect COVID-19 virus.
   Viking Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Corporate Update  2020/02/26 21:15:00 PR Newswire
/PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for…
   The future of these 7 biotechs hinges on their ability to treat a silent liver disease and capture a $9.6 billion market. Here's exactly what investors should be watching for this year.  2020/02/25 18:19:00 Business Insider
There are about 70 drugs in clinical testing for NASH, a fatty liver disease that affects millions of Americans and is a top cause of liver transplants. We identified seven biotechs that have staked their companies — and their stocks — on finding success in NASH in 2020. Those seven are: Intercept Pharmaceuticals, Genfit, NGM Biopharmaceuticals, Akero Therapeutics, Viking Therapeutics, Inventiva Pharma, and 89bio 2019 crumbled into a "graveyard of failures" in NASH, as one Wall Street analyst put it. But the small biotech Intercept stood alone in success. Now, the company has to convince regulators to approve its drug, which would be the first-ever NASH treatment. The other six biotechs we highlight have major clinical trial readouts set for 2020, which could prove transformative for these companies in the hunt for additional NASH therapies. Click here for more BI Prime stories . Big drugmakers have faced years of costly failures in the fight to come up with treatments for the silent liver disease known as NASH.
   5 Stocks Analysts Recommend Heading Into 2020  2020/01/01 17:07:33 Benzinga
The S&P 500 closed out 2019 with another strong month in December. However, analysts remain optimistic on some top stocks heading into 2020. Here’s a look at several stocks analysts recommend. Vivint Solar Inc (NYSE: VSLR ) Vivint shares doubled in 2019, but analysts see more upside ahead in the long-term for Vivint. Of the last 10 analysts to publish research on Vivint, nine gave the stock a bullish rating with an average price target of $9.03, suggesting 18% upside. Glu Mobile Inc. (NASDAQ: GLUU ) Investors have few chances to buy stocks at a discount after the market’s big run in 2019, but Gluu shares are down 24% on the year. Gluu reported disappointing numbers and issued lackluster guidance this year, but Wall Street sees the sell-off as a buying opportunity. The 10 most recent research reports on the company resulted in nine bullish ratings with an $8.28 average price target, suggesting 35% upside. Viking Therapeutics Inc (NASDAQ: VKTX ) Viking is a clinical-stage biotech stock developing VK2809, a drug used to treat non-alcoholic steatohepatitis (NASH).
   Viking Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update  2019/11/05 12:00:00 PR Newswire
SAN DIEGO, Nov. 5, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the third quarter ended…
   5 Stocks Analysts Recommend Heading Into 2020  2020/01/01 17:07:33 Benzinga
The S&P 500 closed out 2019 with another strong month in December. However, analysts remain optimistic on some top stocks heading into 2020. Here’s a look at several stocks analysts recommend. Vivint Solar Inc (NYSE: VSLR ) Vivint shares doubled in 2019, but analysts see more upside ahead in the long-term for Vivint. Of the last 10 analysts to publish research on Vivint, nine gave the stock a bullish rating with an average price target of $9.03, suggesting 18% upside. Glu Mobile Inc. (NASDAQ: GLUU ) Investors have few chances to buy stocks at a discount after the market’s big run in 2019, but Gluu shares are down 24% on the year. Gluu reported disappointing numbers and issued lackluster guidance this year, but Wall Street sees the sell-off as a buying opportunity. The 10 most recent research reports on the company resulted in nine bullish ratings with an $8.28 average price target, suggesting 35% upside. Viking Therapeutics Inc (NASDAQ: VKTX ) Viking is a clinical-stage biotech stock developing VK2809, a drug used to treat non-alcoholic steatohepatitis (NASH).
   Viking Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update  2019/11/05 12:00:00 PR Newswire
SAN DIEGO, Nov. 5, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the third quarter ended…
   Viking Therapeutics to Report Financial Results for Third Quarter 2019 on November 5, 2019  2019/10/31 11:30:00 PR Newswire
SAN DIEGO, Oct. 31, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for…
   Have Insiders Been Buying Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares?  2019/05/14 15:06:37 Yahoo Finance
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift…
   Were Hedge Funds Right About Dumping Viking Therapeutics, Inc. (VKTX) ?  2019/05/09 15:06:17 Yahoo Finance
We can judge whether Viking Therapeutics, Inc. (NASDAQ:VKTX) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There's no better way to get these firms' immense resources and analytical capabilities working for us than
   Viking Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update  2019/11/05 12:00:00 PR Newswire
SAN DIEGO, Nov. 5, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the third quarter ended…
   Viking Therapeutics to Report Financial Results for Third Quarter 2019 on November 5, 2019  2019/10/31 11:30:00 PR Newswire
SAN DIEGO, Oct. 31, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for…
   Have Insiders Been Buying Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares?  2019/05/14 15:06:37 Yahoo Finance
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift…
   Were Hedge Funds Right About Dumping Viking Therapeutics, Inc. (VKTX) ?  2019/05/09 15:06:17 Yahoo Finance
We can judge whether Viking Therapeutics, Inc. (NASDAQ:VKTX) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There's no better way to get these firms' immense resources and analytical capabilities working for us than
   Edited Transcript of VKTX earnings conference call or presentation 2-May-19 8:30pm GMT  2019/05/03 23:14:09 Yahoo Finance
Q1 2019 Viking Therapeutics Inc Earnings Call

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 バイキング・セラピュ―ティクス VKTX Viking Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)